874:HKEXGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H Analysis

S & F Capital Berhad is trading at MYR0.065, which sits above its DCF‑derived fair value of roughly MYR0.05, suggesting limited upside. The price‑to‑book ratio of 0.69 indicates the market is already pricing the stock below book, yet the over‑valuation relative to intrinsic value remains. Revenue has collapsed by 62.6% YoY and margins are deeply negative (gross margin 17%, operating margin –39%, profit margin –19%). The balance sheet is strained with total debt of MYR17.1 million dwarfing cash of MYR3.8 million, yielding a debt‑to‑equity of 27.4. Cash flow is weak, with operating cash outflows of MYR20.8 million and only modest free cash flow. No dividend is paid, confirming the lack of sustainable income for shareholders.
Technically, the 20‑day SMA (0.061) sits below the 50‑day SMA (0.062) and both are under the 200‑day SMA (0.069), reinforcing a bearish bias. The RSI at 52.9 is neutral, while the MACD line has just turned bullish (0.00086 above its signal of 0.00081) but the histogram remains thin. Volume is increasing, yet the price remains near the lower end of its 52‑week range and far from the identified resistance at 0.09. Volatility is extreme at 123% over the past 30 days and the maximum drawdown of 45% underscores the stock’s price fragility. Beta is low at ~0.44, indicating limited market‑wide correlation, but the thin trading volume points to liquidity risk. Given the confluence of weak fundamentals, bearish technical positioning, and heightened volatility, the stock appears unattractive across horizons.